Navigation Links
Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
Date:5/31/2012

MONMOUTH JUNCTION, N.J., May 31, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved the first-ever generic to Delsym®, an extended-release oral liquid suspension containing dextromethorphan polistirex.

Delsym was approved in 1982 and there has never been any generic alternative approved until now. Tris has pioneered the delivery of drugs in taste-neutral, extended release dosage forms such as liquids, ODT/chewable tablets, and strips that are otherwise associated with immediate release. Tris' versatile, patented technology avoids the use of toxic organic solvents by employing aqueous-based coating.

"This is the third extended-release liquid product approved by the FDA based on our patented technology, and speaks to Tris' capabilities to develop and commercialize difficult products," said Ketan Mehta, President & CEO of Tris Pharma.  "Leveraging our technology, Tris has built a robust and deep pipeline of unique products that will address many of today's unmet needs."

Perrigo is Tris' exclusive partner in distributing this product as a store-brand alternative to Delsym, and has announced that it will be shipping the product for the coming cough/cold/flu season.  Annual sales across the entire Delsym brand are estimated at more than $100 million.

Delsym is a registered trademark of Reckitt Benckiser, which is not associated with Tris Pharma or Tris' generic product.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
3. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
4. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
5. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
6. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
7. Isis Pharmaceuticals to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
9. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
10. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
11. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... Drs. Mario Canal and Ben ... 20, 2020 at The Mansion in Voorhees. The course features guest speaker, Dr. Amanda ... implants. Dental implants, including All-on-4® full mouth dental implants, are a ...
(Date:2/19/2020)... , ... February 19, 2020 ... ... notebook platform for research data management, has released a new SnapGene ... data management features. With a ‘Quick View’ of supported DNA files, the ...
(Date:2/19/2020)... ... February 19, 2020 , ... The swine flu (H1N1) was the virus that ... a potential new outbreak. Although the U.S. has eradicated this disease after its ... countries in the world, posing a risk from trading partners. , In a ...
Breaking Medicine Technology:
(Date:2/21/2020)... (PRWEB) , ... February 21, 2020 , ... ... to host the 2021 World Cancer Leaders’ Summit in Boston, MA, in October ... brings together key decision makers including prime ministers, ministers of health, city and ...
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... Millennial women ... Surgery & Laser Center in Milford, Penn requesting treatments to achieve “ Rich Girl ... it doesn’t look like it is slowing down into 2020. It’s a look inspired ...
(Date:2/19/2020)... , ... February 19, 2020 , ... ... of and application deadline for its new Lifestyle Medicine Residency Curriculum (LMRC). The ... integrated implementation into medical residency programs. Driven by resident involvement, the curriculum ...
(Date:2/19/2020)... NEEDHAM, Mass. (PRWEB) , ... February 19, 2020 ... ... improve the quality and consistency of healthcare delivery, announced that it will participate ... 13, 2020, in Orlando, Florida. BPM+ Health will engage healthcare professionals and other ...
(Date:2/16/2020)... ... 16, 2020 , ... Accumen Inc., the leader in healthcare ... The Joint Commission to provide a complimentary series of Patient Blood Management (PBM) ... transfusion safety officers) within U.S. hospitals. , “Accumen’s mission is to ...
Breaking Medicine News(10 mins):